Trial Profile
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Ondansetron/pyridostigmine (Primary) ; Pyridostigmine
- Indications Myasthenia gravis
- Focus Adverse reactions
- Sponsors DAS Therapeutics
- 22 Apr 2022 Planned End Date changed from 30 Apr 2022 to 30 Apr 2023.
- 22 Apr 2022 Planned primary completion date changed from 30 Apr 2022 to 30 Apr 2023.
- 07 Apr 2021 Planned End Date changed from 30 Sep 2021 to 30 Apr 2022.